Resources | NITAG RESOURCE CENTER

2023 ∙ ACIP

Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023

2023 ∙ NACI

Guidance on the use of COVID-19 vaccines in the fall of 2023

2023 ∙ NACI

NACI Interim guidance on the use of bivalent Omicroncontaining COVID-19 vaccines for primary series

2023 ∙ NACI

Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19

2023 ∙ NACI

Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix

2023 ∙ NACI

Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines

2023 ∙ NACI

Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations

2023 ∙ NACI

NACI guidance on COVID-19 vaccine booster doses: Initial considerations for 2023

2022 ∙ Dhanani, Lindsay Y. Franz, Berkeley

A Meta-Analysis of COVID-19 Vaccine Attitudes and Demographic Characteristics in the United States

2022 ∙ Ripon, R. K. Motahara, U. Alam, A. Ishadi, K. S. Sarker, M. S.

A meta-analysis of COVID-19 vaccines acceptance among Black /African American